ViiVHealthcare US

You are about to leave ViiVMedinfo.
 

By clicking "Allow," you will be taken to a website that is independent of ViiV Healthcare. The site you linking to is not controlled or endorsed by ViiV Healthcare, and ViiV Healthcare is not responsible for the content provided on that site.

This site is intended for US healthcare professionals only.

  • HIV Prevention
  • HIV Treatment
  • Pediatric HIV
  • Report an Adverse Event
ViiVHealthcare
  • Home
  • Congress Presentations
  • HIV Resources
    • HIV Prevention
    • HIV Treatment
    • Pediatric HIV
    • Videos and Events
    • Medical Resources
  • Our HIV Medicines
  • Our Pipeline
  • Connect With Us
    • Our HIV Experts
    • Connect With Us
ViiVHealthcare
  • Home
  • Congress Presentations
  • HIV Resources
    • HIV Prevention
    • HIV Treatment
    • Pediatric HIV
    • Videos and Events
    • Medical Resources
  • Our HIV Medicines
  • Our Pipeline
  • Connect With Us
    • Our HIV Experts
    • Connect With Us
Our HIV Medicines
Show Medicines
Hide Medicines
OUR HIV MEDICINES
  • Apretude
  • Cabenuva
  • Dovato
  • Tivicay / Tivicay PD
  • Juluca
  • Rukobia
  • Triumeq / Triumeq PD
  • Vocabria
  • Combivir
  • Epivir
  • Epzicom
  • Retrovir
  • Selzentry
  • Lexiva
  • Trizivir
  • Viracept
  • Ziagen

Rukobia

(fostemsavir)

Rukobia, a HIV-1 gp120-directed attachment inhibitor.

eLearning Modules: Learn more about Fostemsavir

Prescribing Information

Patient Information

Talk to a Medical Expert

  • Medical Information Documents

    • Overview of HTE Patients

      Overview (MI letter)

      HTE Resources

    • BRIGHTE Study

      Immunologic Recovery

      Use with Ibalizumab

      BRIGHTE Overview (MI letter)

      BRIGHTE Overview (Infographic)

      Week 96 Results (IAS 2019)

      Prior ARV Exposure and Optimized Background Therapy

      OBT (MI letter)

      OBT (Infographic)

    • Clinical Pharmacology

      MOA (MI letter)

      CNS Penetration

      Binding Affinity/Dissociation

    • Viral Susceptibility and Cross-Resistance

      Viral susceptibility (MI letter)

      Viral susceptibility (Infographic)

    • Safety Data

      Safety Summary

      QTc Prolongation

      Data in Pregnancy

    • Drug-Drug Interactions

      DDI Overview

    • Once Daily Use

      Once Daily Use

    • Storage and Stability

      Splitting/Crushing

      Storage Conditions

  • On Demand Medical Videos

    • Dosing

      Fostemsavir Clinical Pharmacology Overview

      Fostemsavir Clinical Pharmacology Overview

      Golkoo Morcos, PharmD, Medical Science Liason

      Fostemsavir Clinical Pharmacology Overview

      Golkoo Morcos, PharmD, Medical Science Liason
    • MOA

      Fostemsavir Mechanism of Action

      Fostemsavir Mechanism of Action

      Golkoo Morcos, PharmD, Medical Science Liason

      Fostemsavir Mechanism of Action

      Golkoo Morcos, PharmD, Medical Science Liason
    • On Demand

      Discussing the BRIGHTE Study at AIDS 2022

      Discussing the BRIGHTE Study at AIDS 2022

      Bruce Gilliam, MD, FACP Sr. Medical Director, North American Medical Affairs
      Dr. Moti Ramgopal, MD, FIDSA, FACP Associate Professor of Medicine Medical Director Midway Reasearch Center and Found of Midway Specialty Care Centers

      Discussing the BRIGHTE Study at AIDS 2022

      Bruce Gilliam, MD, FACP Sr. Medical Director, North American Medical Affairs
      Dr. Moti Ramgopal, MD, FIDSA, FACP Associate Professor of Medicine Medical Director Midway Reasearch Center and Found of Midway Specialty Care Centers
      Caring for Patients with Multidrug Resistant (MDR) HIV - A Focus on Patient Identification and ARV Management with Q&A

      Caring for Patients with Multidrug Resistant (MDR) HIV - A Focus on Patient Identification and ARV Management with Q&A

      Alftan Dyson, PharmD | Bruce Gilliam, MD | Elizabeth Race, MD, MPH| Moti Ramgopal, MD, FACP, FIDSA

      Caring for Patients with Multidrug Resistant (MDR) HIV - A Focus on Patient Identification and ARV Management with Q&A

      Alftan Dyson, PharmD | Bruce Gilliam, MD | Elizabeth Race, MD, MPH| Moti Ramgopal, MD, FACP, FIDSA
    • Pharmacokinetics

      Fostemsavir Clinical Pharmacology Overview

      Fostemsavir Clinical Pharmacology Overview

      Golkoo Morcos, PharmD, Medical Science Liason

      Fostemsavir Clinical Pharmacology Overview

      Golkoo Morcos, PharmD, Medical Science Liason
    • Virology/Resistance

      Viral Susceptibility of Rukobia

      Viral Susceptibility of Rukobia

      Golkoo Morcos, PharmD, US Medical Director

      Viral Susceptibility of Rukobia

      Golkoo Morcos, PharmD, US Medical Director
    • Clinical Pharmacology

      Clinical Pharmacology Overview

      Clinical Pharmacology Overview

      Clinical Pharmacology Overview

      MOA Overview (Video)

      MOA Overview (Video)

      MOA Overview (Video)

    • Viral Susceptibility and Cross-Resistance

      Viral susceptibility (Video)

      Viral susceptibility (Video)

      Viral susceptibility (Video)

      Data with IBA or MVC (CROI 2021)

      Data with IBA or MVC (CROI 2021)

      Data with IBA or MVC (CROI 2021)

  • External Resources

    For more information on Genotype interpretation, visit the following resources:

     

    ANRS HIV French Resistance
    www.hivfrenchresistance.org

     

    IAS-USA, website
    www.iasusa.org

     

    Los Alamos database
    www.hiv.lanl.gov

     

    Stanford HIV Drug Resistance database
    hivdb.stanford.edu

    For more information on OBT construction for specific patient, visit the following resources:

     

    HIV-ASSIST

    Welcome to HIV-ASSIST | HIV-ASSIST (hivassist.com)

     

    AIDS Education Training Center

    National Coordinating Resource Center
    aidsetc.org

    Regional AETCs

    http://aidsetc.org/aetc-program/regional-offices

     

    Mayo Clinic: POINT-OF-CARE CME – Highly Treatment–Experienced and Complex HIV Cases (Education and Research at Mayo Clinic - Education and Research at Mayo Clinic)

    POINT-OF-CARE CME - Highly Treatment–Experienced and Complex HIV Cases

     

    Medscape
    www.medscape.com

     

    National Clinical Consultation Center
    nccc.ucsf.edu/clinical-resources/hiv-aids-resources

    For more information on General Information about OBT Construction, visit the following resources:

    Clinical Care Options
    www.clinicaloptions.com/hiv

     

    DHHS Guidelines
    https://clinicalinfo.hiv.gov/

     

    In Practice
    www.inpractice.com/Textbooks/HIV

     

    Medscape
    www.medscape.com

     

    National HIV Curriculum
    www.hiv.uw.edu

     

    Practice Point
    www.practicepointcme.com

     

    UCSF HIV InSITE
    http://hivinsite.ucsf.edu

     

    Up to date
    www.uptodate.com

  • Talk to Medical Expert
  • Request a Scientific Discussion
  • Chat

Connect With Us

ViiVHealthcare US

Are you a US healthcare provider?
 

This web portal is intended as an educational resource for healthcare providers practicing in the United States. It may include information about products or uses that have not been approved by the US Food and Drug Administration.
 

If you are not a healthcare provider, please discuss any questions you have regarding your health or medicines with your doctor, pharmacist, or nurse.
 

Yes

No

Connect With Our Medical Experts

Find My ViiV MSL

Easily find the ViiV Medical Science Liaison (MSL) in your area.

Talk to a Medical Expert

Connect now with a live ViiV Medical Expert.

Request a Scientific Discussion

Submit a request for additional information from a ViiV Medical Expert.

Contact Us

Chat Live

Get immediate assistance from a ViiV Healthcare Professional.

Call 1‑888‑226‑8434

Weekdays from 8 AM to 6 PM ET
(5 AM – 3 PM PT)

Our Response to COVID-19

Report an Adverse Event

To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at 1‑877‑844‑8872 or FDA at 1‑800‑332‑1088 or www.fda.gov/medwatch

ViiVHealthcare US

This site is intended for US Healthcare Professionals Only. It may include information about products or uses that have not been approved by the US Food and Drug Administration.

 

Trademarks are owned by or licensed to the ViiV Healthcare group of companies.

 

©2022 ViiV Healthcare group of companies or its licensor. Produced in USA. January 2022

  • Terms of Use
  • Cookie Policy
  • Privacy Notice
  • Terms and Conditions
  • ViiVHealthcare.com